A living WHO guideline on drugs to prevent covid-19

@article{Lamontagne2021ALW,
  title={A living WHO guideline on drugs to prevent covid-19},
  author={François Lamontagne and Thomas Agoritsas and Reed Alexander Siemieniuk and Bram Rochwerg and Jessica Julia Bartoszko and Lisa M Askie and Helen Macdonald and Wagdy Amin and Fr{\'e}d{\'e}rique Jacqu{\'e}rioz Bausch and Erlina Burhan and Maurizio Cecconi and D. Chanda and Vu Quoc Dat and Bin Du and Heike Geduld and Patrick O Gee and Harley Nerina and Madiha Hashimi and Beverley J. Hunt and Sushil Kumar Kabra and Seema Kanda and Leticia Kawano-Dourado and Yae-Jean Kim and Niranjan Kissoon and Arthur Kwizera and Yee Sin Leo and Imelda C Mahaka and H{\'e}la Manai and Greta Mi{\~n}o and Emmanuel Fru Nsutebu and Natalia Yu. Pshenichnaya and Nida Qadir and Shalini Sri Ranganathan and Saniya R Sabzwari and Rohit Sarin and Mike Sharland and Yinzhong Shen and Jo{\~a}o Paulo Souza and Miriam Songa Stegemann and S. Canales Ugarte and Sridhar Venkatapuram and Dubula Vuyiseka and Jacobus Preller and Romina Brignardello-Petersen and Elena Kum and Anila Qasim and Dena Zeraatkar and Andrew Owen and Gordon H. Guyatt and Lyubov Lytvyn and Janet Diaz and Per Olav Vandvik and Michael R. Jacobs},
  journal={BMJ},
  year={2021},
  volume={372}
}
Abstract Clinical question What is the role of drugs in preventing covid-19? Why does this matter? There is widespread interest in whether drug interventions can be used for the prevention of covid-19, but there is uncertainty about which drugs, if any, are effective. The first version of this living guideline focuses on the evidence for hydroxychloroquine. Subsequent updates will cover other drugs being investigated for their role in the prevention of covid-19. Recommendation The guideline… 

The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions

TLDR
The World Health Organization (WHO) living guideline on drugs to prevent COVID-19 should retract the advice to stop research on hydroxychloroquine chemoprophylaxis, should correct its errors, and should revise its guidance.

The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions.

TLDR
In the three pre-exposure chemoprophylaxis RCTs evaluated in the guideline there were no deaths and only two COVID-19-related hospital admissions, and there was a mistake in the analysis of the number of discontinuations.

Drug treatments for covid-19: living systematic review and network meta-analysis

TLDR
Glucocorticoids probably reduce mortality and mechanical ventilation in patients with covid-19 compared with standard care and the effectiveness of most interventions is uncertain because most of the randomised controlled trials so far have been small and have important study limitations.

Prophylaxis against covid-19: living systematic review and network meta-analysis

TLDR
This living network meta-analysis finds that hydroxychloroquine prophylaxis has trivial to no effect on hospital admission and mortality, probably increases adverse effects, and probably does not reduce the risk of SARS-CoV-2 infection.

Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis

TLDR
There is limited evidence for the benefit of ivermectin for COVID-19 treatment and prophylaxis, and most of this evidence is of low quality.

Colchicine for the treatment of COVID-19.

TLDR
The effectiveness and safety of colchicine as a treatment option for COVID-19 in comparison to an active comparator, placebo, or standard care alone in any setting is assessed to maintain the currency of the evidence.

Quality of and Recommendations for Relevant Clinical Practice Guidelines for COVID-19 Management: A Systematic Review and Critical Appraisal

TLDR
The quality of relevant COVID-19 clinical practice guidelines (CPGs) was not encouragingly high, but a few guidelines show Remdesivir may be beneficial for the patients, hydroxychloroquine +/– azithromycin may not, and there were more consistent suggestions regarding discharge management.

Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics.

TLDR
Future clinical trials should be designed to standardize clinical approaches, with appropriate organization, patient selection, addition of control groups, and careful identification of disease phase to reduce heterogeneity and bias and should rely on the integration of scientific societies to promote a consensus on interpretation of the data and recommendations for optimal COVID-19 therapies.

Improving the adherence to COVID-19 preventive measures in the community: Evidence brief for policy

TLDR
The evidence showed that an increase in knowledge, transparent communication, and public awareness about the risks of COVID-19 and the benefits of adopting preventive measures results in changes in people's attitudes and behavior, which can increase adherence.

Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis

TLDR
Patients with non-severe disease randomised to antiviral monoclonal antibodies had lower risk of hospitalisation than those who received placebo, except casirivimab-imdevimab, which may reduce mortality in patients who are seronegative.
...

References

SHOWING 1-10 OF 13 REFERENCES

A living WHO guideline on drugs for covid-19

TLDR
A standing international panel of content experts, patients, clinicians, and methodologists, free from relevant conflicts of interest, produce recommendations for clinical practice, containing a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19, and a weak or conditional recommendation against systemic cortiosteroids for non-severe patients.

A living systematic review protocol for COVID-19 clinical trial registrations

TLDR
This living systematic review will provide a useful resource of COVID-19 clinical trial registrations for researchers in a rapidly evolving context and will allow prioritisation of research targets for individual patient data meta-analysis.

Prophylaxis against covid-19: living systematic review and network meta-analysis

TLDR
This living network meta-analysis finds that hydroxychloroquine prophylaxis has trivial to no effect on hospital admission and mortality, probably increases adverse effects, and probably does not reduce the risk of SARS-CoV-2 infection.

A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19

TLDR
Postexposure therapy with hydroxychloroquine did not prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons exposed to a PCR-positive case patient.

Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial

TLDR
Pre-exposure prophylaxis with hydroxychloroquine once or twice weekly did not significantly reduce laboratory-confirmed Covid-19 or Covid -19-compatible illness among healthcare workers.

Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial

TLDR
In this randomized clinical trial, although limited by early termination, there was no clinical benefit of hydroxychloroquine administered daily for 8 weeks as pre-exposure prophylaxis in hospital-based HCWs exposed to patients with COVID-19.

Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: initial results of a double-blind, placebo-controlled randomized clinical trial

TLDR
First month follow-up analysis displayed that PrEP with hydroxychloroquine at low doses is safe and underpowered, and the study design deemed underpowered to evaluate any benefit regarding PrEP efficacy.

Guidelines International Network: Toward International Standards for Clinical Practice Guidelines

TLDR
G-I-N's proposed set of key components address panel composition, decision-making process, conflicts of interest, guideline objective, development methods, evidence review, basis of recommendations, ratings of evidence and recommendations, guideline review, updating processes, and funding.

Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection

TLDR
This randomized controlled trial tests hydroxychloroquine as postexposure prophylaxis for SARS-CoV-2 infection.